Sleep Disorders | Sleep Review
Healio: A survey of patients with insomnia who participated in two Phase 3 trials evaluating daridorexant found that “improved diurnal function” was the most important treatment outcome for their condition.
The study was one of several abstracts on the oral sleep therapy daridorexant (Idorsia Pharmaceuticals) presented during the virtual SLEEP 2021 meeting.
Daridorexant is an orexin receptor 2 agonist that has been developed to treat insomnia. It’s currently awaiting FDA approval, Emmanuel Mignot, MD, PhD, professor of sleep medicine at Stanford University who studied the drug, told Healio Primary Care.
“The orexin system keeps the brain awake so that it induces sleep differently than classic sleeping pills with benzodiazepine effects such as zolpidem, which work by reducing overall neuronal activity,” he said.
Get the full story at healio.com.